ACRV - Latest News

Acrivon Therapeutics, Inc. Common Stock (ACRV), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $88.2M. Beta to the broader market is 1.86.

The article list below shows the most recent ACRV headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ACRV Headlines

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

globenewswire.com - Aug 31, 2026

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

zacks.com - Aug 24, 2026

Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors?

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

globenewswire.com - Aug 12, 2026

ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

globenewswire.com - Aug 5, 2026

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaini

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

globenewswire.com - Jul 21, 2026

Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for poten

How News Affects ACRV Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ACRV's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ACRV news questions

What is the latest ACRV news headline?

The most recent ACRV headline (Aug 31, 2026) is "Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ACRV news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ACRV news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ACRV options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.